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Nosocomial bronchopneumonia is a frequent complication in patients with chronic intratracheal intubation.
Despite targeted antibiotic treatment, production of abundant bronchial secretion containing pathogen bac-
teria often tends to be chronic, and so mortality drastically increases. This problem led to an investigation of
the penetration of five cephalosporin antibiotics into the sputum. Serum and sputum were collected from 24
chronically intubated patients having purulent nosocomial bronchopneumonia treated in an intensive care unit
(ICU). Patients received the following doses intravenously every 24 h: five received 70 mg/kg of body weight
cefuroxime, four received 110 mg/kg cefamandole, six received 80 mg/kg ceftriaxone, four received 80 mg/kg
ceftazidime, and five received 80 mg/kg cefepime. Antibiotic concentrations in the serum and sputum were
evaluated by capillary electrophoresis. MICs were determined for bacteria isolated from the purulent bronchial
secretions. The mean levels of the cephalosporins in the sputum did not reach the MICs for the bacteria
isolated from the same samples. Ceftriaxone was the only one of the investigated five cephalosporins that had
a measurable concentration in the sputum (1.4  1.2 mg/liter). The low concentration of antibiotics in the
purulent tracheobronchial secretion can be one of the many reasons for ineffective therapy of nosocomial
bronchopneumonia in intubated patients in the ICUs. In the case of intubated or mechanically ventilated
patients having chronic bronchopneumonia, determination of drug concentration in the bronchial secretion
might be considered when selecting an antibiotic for treatment.
Nosocomial bronchopneumonia is a threatening complica-
tion that increases the mortality of hospitalized patients. How-
ever, many risk factors are known that worsen the prognosis to
critical form, especially in comatose patients treated in inten-
sive care units (ICU) (9, 19, 24). The majority of patients lying
unconscious in the ICU are intubated, and some of them are
on respirators. In many cases, these patients undergo one or
more operations, which also increase their susceptibility for
infections. Finally, chronic intratracheal intubation, the possi-
bility of aspiration due to the weakness or lack of the pharyn-
geal and coughing reflex prior to intubation, the reduced im-
mune system of the exhausted host, and long-term immobility
lead to bronchopneumonia (14, 21, 32, 33, 39). Since the causes
of the disease in general cannot be eliminated rapidly, chronic
forms tend to develop and progression to purulent form usu-
ally appears. The basis of therapy is antibiotic treatment, and
the drug is chosen according to the culture results from the
blood or sputum. However, antibiotic therapy is not always
effective (8, 29). The situation is often worsened by nosocomial
infections, when polyresistant bacteria make therapy much
more difficult (7, 13, 22, 36). In our experience, in spite of the
specified antibiotic therapy, cessation of the production of
abundant purulent bronchial secretion that contains patho-
genic bacteria and recovery from bronchopneumonia are long-
term processes. This problem gave rise to our investigation of
the concentrations of five cephalosporins (cefuroxime, cefa-
mandole, ceftriaxone, ceftazidime, and cefepime) in the spu-
tum from patients suffering from nosocomial purulent broncho-
pneumonia in our ICU. To evaluate the effectiveness of the
applied antibiotic therapy in the sputum, the MICs of the inves-
tigated cephalosporins for the cultured bacteria from the sputum
were also determined.
Sample collection and evaluation. Serum and sputum sam-
ples were collected from 24 chronically intubated patients who
suffered from nosocomial bronchopneumonia by procedures
that are in accordance with Hungarian ethical rules. Fourteen
females and 10 males were investigated (mean age, 55.2 12.0
years; range, 44 to 68 years; mean body weight, 67.6  14.5 kg;
range, 53 to 82 kg). All patients were treated in the ICU
because of serious intracranial lesion, and 16 of them were
mechanically ventilated. The average duration of endotracheal
intubation at diagnosis of pneumonia was 5 days; the range was
3 to 7 days. As soon as pneumonia was diagnosed by X-ray,
laboratory investigations, and clinical symptoms, antibiotic
therapy was started, but later it was promptly modified as the
bacterial culture results from blood or sputum arrived. Our
investigations were performed at the beginning of therapy,
when, in each 24-h period, five patients received 70 mg/kg of
body weight cefuroxime, four patients received 110 mg/kg cefa-
mandole, six patients received 80 mg/kg ceftriaxone, four pa-
tients received 80 mg/kg ceftazidime, and five patients received
80 mg/kg cefepime intravenously. Ceftriaxone was adminis-
tered in two equal doses per day; cefuroxime, ceftazidime, and
cefepime were administered in three equal doses per day; and
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cefamandole was administered in four equal doses per day.
Drug concentrations were measured in serum and sputum
samples collected on the second day of treatment 6 hours after
the last dose of antibiotics. Bronchial secretion was sucked out
from the trachea by a sterile suction pipe through the nasotra-
cheal tube.
Bacteria from cultures of the sputum were also isolated, and
the MICs of the cephalosporins for the bacterial strains were
evaluated.
Analysis using CE. The concentration of cephalosporins was
determined by capillary electrophoresis (CE). Serum and spu-
tum samples were stored at 18°C until analysis was per-
formed, 24 h after sample collection. Optimized separation
conditions for different cephalosporin antibiotics using CE
were investigated in our earlier work (16, 17). The developed
method gave satisfactory precision with respect to migration
times (relative standard deviation  1%) and gave linear re-
sponses (R2  0.998) over a concentration range of about 1 to
100 mg/liter for all studied compounds. These concentration
ranges cover the normal therapeutic concentrations of these
antibiotics. The capillary electrophoresis instrument was an
HP3D model (Agilent, Waldbronn, Germany). In all measure-
ments hydrodynamic sample introduction (10 kPa) was used
for injecting samples. The sample solutions were introduced at
the anodic end of the capillary. Separations were performed
using fused-silica capillaries coated on the outside with poly-
imide (Polymicro Technology, Phoenix, AZ). Capillaries were
48.5 cm with an inside diameter of 50 m and an effective
capillary length of 40 cm.. The applied voltage was 25 kV. The
temperature of the capillary holder was kept constant at 25°C.
Detection was carried out by on-column photometric measure-
ment at 270 nm. The electropherograms were recorded and
processed by the ChemStation computer program, version 7.01
(Agilent). Before use, the capillaries were preconditioned with
the buffer electrolyte for 10 min. During analysis of biofluid
samples, the capillaries were also postconditioned after each
run by flushing with 0.3 M sodium dodecyl sulfate (2 min), 0.5
M NaOH (6 min), and distilled water (2 min) to remove all the
proteinaceous components, which have a high tendency to
stick to the capillary walls.
The serum samples were defrosted immediately before anal-
ysis. Since the highly viscous sputum sample could not be
injected directly into the capillary, 1 g of these samples was
lyophilized and then dissolved in 500 l methanol-water (1:1)
prior to analysis. The suitability of sample pretreatment of
sputum and other highly viscous biological samples using ly-
ophilization and dissolution before the CE analysis was inves-
tigated and validated in detail. Electrophoretic runs were per-
formed as quickly as possible and not later than 4 h after
sample preparation.
Determination of MICs. Pure cultures of the bacteria were
tested. The antibiotic was dissolved in double-distilled water.
The stock solutions were stored at30°C for 2 weeks; working
solutions were stored at 4°C for a maximum of 24 h. The
inoculum was prepared as follows. Isolated colonies from
blood agar were grown in Mueller-Hinton broth (Oxoid) for
18 h at 37°C. The strains were diluted in Mueller-Hinton broth
to yield an inoculum of 1.5  105 CFU per ml. The stock
solutions of antibiotics were serially twofold diluted in Muel-
ler-Hinton broth to obtain working concentrations of 0.016,
0.032, 0.064, 0.128, 0.25, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, and 64.0
g/ml. Ninety-microliter amounts from broth containing two-
fold concentration increments of antimicrobial agents were
added to 96-well microdilution trays. In general, the plate was
prepared on the day before inoculation. Each well was inocu-
lated with 10 l bacterial suspension. Thus, the final inoculum
was 1.5  104 CFU/ml. The strains were also inoculated on
antibiotic-free control plates. Growth (turbidity) of aerobic
strains was recorded after 18 h at 37°C. The MIC was reported
as the lowest concentration of the antibiotic at which no growth
was recorded (34).
Observations. The concentrations of the cephalosporins in
the serum 6 hours after intravenous drug administration were
as follows: cefuroxime, 26.9  4.9 mg/liter; cefamandole,
41.5 10.6 mg/liter; ceftazidime, 9.1  2.0 mg/liter; ceftriax-
one, 64.8  20.8 mg/liter; cefepime, 28.2  25.3 mg/liter.
The levels of cefuroxime, cefamandole, ceftazidime, and
cefepime in the sputum remained under 0.5 mg/liter, but the
concentration of ceftriaxone was 1.4  1.2 mg/liter (Table 1.).
TABLE 1. Mean concentrations of five cephalosporins in the serum
and sputum 6 hours after intravenous drug administration
Cephalosporin No. of cases
Mean concn (mg/liter)  SD in:
Serum Sputum
Cefuroxime 5 26.9 4.9 0.5
Cefamandole 4 41.5 10.6 0.5
Ceftriaxone 6 64.8 20.8 1.4 1.2
Ceftazidime 4 9.1 2.0 0.5
Cefepime 5 28.2 25.3 0.5
TABLE 2. MICs for nine bacterial strains from sputum of five cephalosporins
Bacterial species No. of cases
MIC (mg/liter) of:
Cefuroxime Cefamandole Ceftriaxone Ceftazidime Cefepime
Klebsiella pneumoniae 3 4 4 2 2 2
Acinetobacter baumannii 5 16 64 16 2 8
Citrobacter freundii 2 64 64 2 8 2
Pseudomonas aeruginosa 3 1,024 64 64 2 2
Escherichia coli 4 4 4 2 2 2
Proteus mirabilis 1 2 4 2 4 8
Enterobacter cloacae 3 4 32 2 4 2
Staphylococcus aureus 5 8 2 8 8 8
Staphylococcus epidermidis 4 2 2 2 4 2
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Nine bacterial strains were isolated from the sputum cul-
tures of the investigated 24 patients. In 10 cases, two bacteria
were found in the tracheobronchial secretion. The results of
the MICs for the bacteria are detailed in Table 2. The MICs of
the investigated five cephalosporins exceed the mean concen-
trations of cephalosporins in the sputum. In two cases, the level
of ceftriaxone in the sputum was higher than 2.0 mg/liter (2.2
and 3.8 mg/liter), which is theoretically high enough for treat-
ing six of the nine bacterial strains, but in both cases MICs for
the bacteria were over 4 mg/liter (Acinetobacter baumannii and
Staphylococcus aureus).
Discussion. Medicinal treatment of bronchopneumonia for
chronically intubated patients in intensive care units always
means a considerable effort for the clinicians (12, 19, 23).
Pulmonary complications in unconscious patients in neurosur-
gical ICU can also decrease the chances for a satisfactory
outcome (15, 31). If production of purulent bronchial secre-
tion becomes chronic in spite of the antibacterial therapy,
the likelihood of developing polyresistant bacterial strains
increases. Nosocomial infections especially impede treat-
ment, although there are some therapeutic guidelines in the
literature (3–5, 28, 39).
The therapeutic benefits of the different cephalosporins
have been often described, and their wide spectrum of effec-
tiveness often distinguishes them among the chosen antibiotics
(11, 26–28). Cefuroxime (6, 18), cefamandole (38), ceftriaxone
(20, 25, 35), ceftazidime (3, 11, 37), and cefepime (5) also are
recommended antibiotics for treating pneumonia. The abun-
dant bronchial secretion from purulent bronchopneumonia in
chronically intubated comatose patients serves as a suitable
medium for bacteria, which makes therapy many times more
difficult. Some tests of the antibiotic concentrations in sputum
have already been carried out (10, 20, 25, 35, 37). Although
antibiotics could be detected in the majority of the measure-
ments, the concentration of the investigated drug did not al-
ways reach the MIC of the bacterial strains found in the sam-
ples (6). In some other studies, the determined drug levels
were low (1, 18, 25), but there are reports of appropriate
antibiotic concentration in the sputum, too (2, 11, 30, 37). In
consideration of the wide spectrum of the reported results and
the low number of measurements directly in purulent secre-
tion, further pharmacodynamical investigations are still
needed.
The high mortality rate and the long-lasting treatment pe-
riod for patients with nosocomial bronchopneumonia despite
the specified antibiotic therapy led to the investigation of the
presence of antibiotics in bronchial secretions after intrave-
nous drug administration. The level of antibiotics in serum
corresponded to the reported results in the literature, but only
the mean concentration of ceftriaxone exceeded the 0.5-mg/
liter detectability level in the sputum while cefuroxime, cefa-
mandole, ceftazidime, and cefepime remained under this level,
and the mean concentrations of all investigated antibiotics did
not reach the MICs for the bacteria isolated from the purulent
bronchial secretion (Tables 1 and 2).
Conclusions. In spite of the targeted treatment based on the
culture from the copious sputum from nosocomial broncho-
pneumonia in intubated comatose patients, the therapy seems
to be often ineffective. One of the main reasons for this clinical
experience can be the low concentrations of the drugs—in this
case five cephalosporins—in the purulent bronchial secretion.
The fast and economical method for detection of drug concen-
tration in the sputum by capillary electrophoresis can help to
check the real effectivity of the applied antibiotic. In the case of
intubated or mechanically ventilated patients that have chronic
bronchopneumonia caused by nosocomial infections, drug
monitoring by determination of its concentration in the bron-
chial secretion might be a method to consider to facilitate
appropriate drug selection.
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